Prescient Therapeutics Limited · ASX:PTX

Prescient Therapeutics Limited financial statements

Prescient Therapeutics Limited's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue4.36M3.71M2.43M1.89M1.19M1.03M72.1K939.8K166.2K
Cost of revenue110.3K7172.09K1.40K4749041.34K1.47K605
Gross profit-110.3K4.36M3.71M2.43M1.89M1.19M1.03M1.65M938.3K1.22M
Research and development5.28M6.72M6.97M6.22M3.40M2.50M2.76M3.68M2.06M2.43M
Selling, general and administrative5.31M1.46M1.49M1.35M1.11M961.5K1.13M1.86M929.4K1.33M
Operating income-10.6M-7.54M-7.19M-9.89M-7.10M-5.43M-4.49M-3.79M-3.61M-3.76M
Depreciation and amortization110.3K5.30K7172.09K1.40K4749041.34K1.47K605
EBITDA-10.5M-7.53M-7.19M-9.88M-7.10M-5.43M-4.49M-3.79M-3.60M-3.76M
Interest expense10.7K6.53K10.6K4.19K3.30K2.20K0
Income before tax-10.4M-7.32M-11.9M-9.37M-6.87M-4.15M-4.35M-3.80M-3.51M-2.57M
Income tax-3.44M-4.36M-3.71M-2.37M-1.75M-1.19M-1.03M-1.63M-940.0K-1.06M
Net income-7.00M-7.32M-8.24M-7.00M-5.12M-4.15M-3.32M-3.80M-2.57M-2.57M
Earnings per share, basic-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.02-0.01-0.01

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents9.03M6.91M10.5M5.90M12.3M16.1M7.36M9.64M5.49M7.65M
Short-term investments20.0K20.0K4.02M16.0M20.0K20.0K20.0K20.0K20.0K20.0K
Receivables3.70M264.3K3.92M2.58M1.72M1.24M1.06M1.75M939.2K1.06M
Inventory246.3K11267.7K111
Current assets14.0M12.9M18.7M24.7M14.2M17.6M8.71M11.6M6.62M8.86M
Property, plant and equipment7.40K2.10K2.82K4.90K1.88K389422.28K2.23K
Total assets16.3M14.6M20.4M28.1M17.6M21.0M12.1M15.0M9.99M12.2M
Accounts payable902.0K3.04M1.72M1.78M505.3K232.6K479.9K393.2K243.2K340.8K
Current liabilities1.96M3.16M2.32M2.03M809.1K514.7K864.2K668.0K543.8K440.6K
Total debt223.0K330.5K165.8K156.9K156.9K56.0K
Total liabilities2.08M3.17M2.33M2.03M856.0K539.7K884.0K685.8K551.6K444.9K
Shareholders' equity14.2M11.4M18.1M26.1M16.8M20.4M11.2M14.3M9.44M11.8M
Shares outstanding1.03B805.3M805.3M727.5M647.8M611.8M394.3M244.5M215.2M213.8M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-7.22M-7.24M-7.40M-6.19M-4.31M-3.97M-2.32M-4.20M-2.15M-3.28M
Capital spending00-30-4.43K-2.31K-2.31K-2.31K-1.52K-1.69K
Free cash flow-7.22M-7.24M-7.40M-6.19M-4.32M-3.97M-2.32M-4.20M-2.15M-3.28M
Cash from investing4.00M12.0M-16.0M-4.43K-2.31K-2.31K-2.31K-1.52K-21.7K
Cash from financing9.34M-330.5K18.1K15.8M428.3K12.7M12.7M8.37M-6351.22M
Dividends paid-12.7M-7.67M-2.47K
Share buybacks-683.2K018.1K16.5M594.1K-836.6K-836.6K-699.5K-1.84K-134.5K
Change in cash2.12M-3.59M4.60M-6.37M-3.83M8.74M-2.30M4.15M-2.16M-2.11M